JRD0049 Slow Virus Packaging Technology Service
Chronic virus packaging technology services Genes developed based on HIV-1 (human immunodeficiency 1 virus) The treatment carrier belongs to the reverse transcription viral department, which is an RNA virus. Different from a general reverse transcription viral vector, it has infected capabilities for split cells and non-split cells. The vector can effectively integrate foreign genes to host chromosomes to achieve persistence expression. At present, the slow virus is also widely used in the study of RNAi. Since in vitro synthesis siRNA is usually short-lived, it is generally limited so that it is limited. Based on The strategy of transferring to intracellular transcriptional siRNA is not only increased by effective transfected cell species, but also a long-term stable inhibitory gene in cells Medium expression. Infection capabilities can effectively infect multiple types of cells such as neuronal cells, hepatocytes, stem cells, and achieve good gene therapeutic effects, and have been launched in the United States. The effect is ideal Therefore, there is a broad application prospect.
The company is currently mainly providing high-quality slow virus (high titer, high purity), applied to clinical experiments and The overall animal experiments for various types of viral particles for different genes and drug targets.After the package is fake viral particles, it can be used for:
It is very difficult to transfecture cells such as neuronal cells, primary cells, stem cells, tumor cells, etc., which are close to transfection efficiency of such cells slow viral vectors; A monoclonal cell line with stable expression or silence specific gene was constructed;
A genetic operation of the living animal model (in Vivo); can be regulated Expressing, a particular element-modified lentiviral expression vector can realize that only the expression of the specific exogenous or endogenous substance can be generated, thereby regulating the timing and quantitative expression of the target gene.